Wellington Management Group LLP Aerie Pharmaceuticals Inc Transaction History

Wellington Management Group LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $227,523 - $543,985	-35,718 Reduced 13.35%	231,847 $3.51 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $340,069 - $590,900	60,296 Added 29.09%	267,565 $2.44 Million
Q4 2021 Feb 11, 2022	BUY	$7.02 - $13.33 $1.46 Million - $2.76 Million	207,269 New	207,269 $1.46 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $407,048 - $648,422	-31,025 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$9.12 - $14.49 $7.43 Million - $11.8 Million	-814,934 Reduced 96.33%	31,025 $418,000
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $2.76 Million - $3.81 Million	-263,799 Reduced 23.77%	845,959 $9.96 Million
Q2 2020 Aug 14, 2020	SELL	$12.0 - $16.13 $67.5 Million - $90.8 Million	-5,626,464 Reduced 83.53%	1,109,758 $16.4 Million
Q1 2020 May 14, 2020	BUY	$11.84 - $25.52 $5.86 Million - $12.6 Million	495,181 Added 7.93%	6,736,222 $90.9 Million
Q4 2019 Feb 11, 2020	BUY	$17.72 - $25.1 $111 Million - $157 Million	6,241,041 New	6,241,041 $151 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.